***Background.*** *Klebsiella pneumoniae* carrying the carbapenemase KPC have become established in medical centers in New York City. At the height of the problem in 2006, over one third of *K. pneumoniae* isolates were found to be carrying this beta-lactamase.

***Methods.*** A three month surveillance study was conducted from November 2013-January 2014 involving 11 hospitals in New York City. All unique patient isolates of *K. pneumoniae* were gathered from hospital microbiology laboratories. Susceptibility testing was performed by the agar dilution method according to CLSI methods. Cephalosporin-resistant isolates were screened by PCR for the presence of *bla*~KPC~. Rates of *K. pneumoniae* positive for *bla*~KPC~ were compared to similar surveillance studies conducted in 2006 and 2009 for nine hospitals in Brooklyn, NY. Rates of KPC-possessing isolates from 2006 and 2013-2014 were compared by Fishers\' exact test.

***Results.*** A total of 944 isolates of *K. pneumoniae* were collected in the 2013-2014 surveillance study. Overall susceptibility rates include: 68% to ceftazidime, 80% to piperacillin-tazobactam, and 86% to meropenem. Of the 944 isolates, 125 (13%) were found to be carrying *bla*~KPC~.

Nine hospitals participated in similar surveillance studies conducted in 2006 and 2009. The percentages of KPC-possessing isolates for the nine hospitals during the three surveillance studies are given in the table.

               2006            2009            2013--2014      P value (2006 vs. 2013-2014)
  ------------ --------------- --------------- --------------- ------------------------------
  Hospital A   21/76 (28%)     24/97 (25%)     10/99 (10%)     P=0.002
  Hospital B   17/42 (40%)     21/55 (38%)     2/42 (4.8%)     P\<0.001
  Hospital C   39/108 (36%)    5/84 (6.0%)     4/53 (7.5%)     P\<0.001
  Hospital D   7/17 (41%)      13/29 (45%)     17/35 (49%)     P=NS
  Hospital E   31/92 (34%)     52/114 (46%)    15/42 (36%)     P=NS
  Hospital F   21/86 (24%)     11/97 (11%)     10/158 (6.3%)   P\<0.001
  Hospital G   70/142 (49%)    39/133 (29%)    22/126 (17%)    P\<0.001
  Hospital H   44/119 (37%)    28/124 (23%)    13/129 (10%)    P\<0.001
  Hospital I   15/54 (28%)     7/55 (13%)      2/60 (3.3%)     P\<0.001
  Total        265/737 (36%)   200/788 (25%)   95/744 (13%)    P\<0.001

***Conclusion.*** Since the height of the problem in 2006, steady and significant progress has been made in reducing the rates of *bla*~KPC~-carrying *K. pneumoniae* in most hospitals in Brooklyn, NY. However, some hospitals continue to struggle with this pathogen.
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